Compare Stocks

Date Range: 

 TRACON PharmaceuticalsGenocea BiosciencesAziyo BiologicsAyala PharmaceuticalsBrainstorm Cell Therapeutics
SymbolNASDAQ:TCONNASDAQ:GNCANASDAQ:AZYONASDAQ:AYLANASDAQ:BCLI
Price Information
Current Price$6.30$2.42$11.03$10.16$3.12
52 Week RangeBuyBuyBuyBuyBuy
MarketRank™
Overall Score1.71.61.41.31.3
Analysis Score3.53.53.53.43.5
Community Score2.82.82.92.73.0
Dividend Score0.00.00.00.00.0
Ownership Score1.70.80.00.00.0
Earnings & Valuation Score0.60.60.60.60.0
Analyst Ratings
Consensus RecommendationBuyBuyBuyBuyBuy
Consensus Price Target$16.67$7.25$20.00$24.20$12.00
% Upside from Price Target164.55% upside199.59% upside81.32% upside138.19% upside284.62% upside
Trade Information
Market Cap$103.72 million$131.12 million$115.15 million$134.53 million$115.49 million
Beta2.022.33N/AN/A0.37
Average Volume400,207513,69319,01330,8641,002,256
Sales & Book Value
Annual Revenue$3 millionN/AN/A$2.33 millionN/A
Price / Sales32.51N/AN/A57.74N/A
CashflowN/AN/AN/AN/AN/A
Price / CashN/AN/AN/AN/AN/A
Book Value$0.67 per share$0.89 per shareN/AN/A($0.54) per share
Price / Book9.40N/AN/AN/A
Profitability
Net Income$-22,670,000.00$-38,950,000.00N/A$-17,790,000.00$-23,250,000.00
EPS($7.47)($2.09)N/AN/A($1.06)
Trailing P/E RatioN/AN/A0.000.00N/A
Forward P/E RatioN/AN/AN/AN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net MarginsN/AN/AN/A-850.81%N/A
Return on Equity (ROE)-273.66%-237.31%N/A-625.24%-339.86%
Return on Assets (ROA)-84.56%-62.30%N/A-70.31%-144.74%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity Ratio0.13%N/AN/AN/AN/A
Current Ratio2.76%3.79%N/A8.63%4.72%
Quick Ratio2.76%3.79%N/A8.63%4.72%
Ownership Information
Institutional Ownership Percentage42.03%53.78%N/A12.81%21.58%
Insider Ownership Percentage23.30%2.08%N/AN/A22.10%
Miscellaneous
Employees18721553440
Shares Outstanding15.48 million53.52 million10.23 million13.24 million36.32 million
Next Earnings DateN/A7/22/2021 (Estimated)8/3/2021 (Estimated)6/28/2021 (Estimated)8/4/2021 (Estimated)
OptionableNot OptionableOptionableNot OptionableNot OptionableOptionable
SourceHeadline
Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Sees Significant Drop in Short InterestBrainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Sees Significant Drop in Short Interest
americanbankingnews.com - May 4 at 7:40 AM
Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Expected to Announce Earnings of -$0.24 Per ShareBrainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Expected to Announce Earnings of -$0.24 Per Share
americanbankingnews.com - April 30 at 6:22 PM
Equities Analysts Set Expectations for Brainstorm Cell Therapeutics Inc.s Q2 2021 Earnings (NASDAQ:BCLI)Equities Analysts Set Expectations for Brainstorm Cell Therapeutics Inc.'s Q2 2021 Earnings (NASDAQ:BCLI)
americanbankingnews.com - April 30 at 7:25 AM
Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Is Worth Evaluating At $3.63Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Is Worth Evaluating At $3.63
marketingsentinel.com - April 29 at 9:26 AM
BCLI: Continuing to Receive Feedback on Next Steps for NurOwn®…BCLI: Continuing to Receive Feedback on Next Steps for NurOwn®…
finance.yahoo.com - April 28 at 7:12 PM
Brainstorm Cell Therapeutics (NASDAQ:BCLI) Issues  Earnings ResultsBrainstorm Cell Therapeutics (NASDAQ:BCLI) Issues Earnings Results
americanbankingnews.com - April 27 at 7:18 AM
BrainStorm Announces First Quarter 2021 Financial Results and Provides a Corporate UpdateBrainStorm Announces First Quarter 2021 Financial Results and Provides a Corporate Update
finance.yahoo.com - April 26 at 8:56 AM
Brainstorm Cell Therapeutics (BCLI) Set to Announce Earnings on MondayBrainstorm Cell Therapeutics (BCLI) Set to Announce Earnings on Monday
americanbankingnews.com - April 20 at 9:30 AM
What Type Of Shareholders Own The Most Number of Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Shares?What Type Of Shareholders Own The Most Number of Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Shares?
nasdaq.com - April 9 at 1:10 PM
Do Institutions Own Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Shares?Do Institutions Own Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Shares?
finance.yahoo.com - April 7 at 8:17 AM
BCLI: Positive Proof-of-Concept Data for NurOwn in Progressive Multiple Sclerosis…BCLI: Positive Proof-of-Concept Data for NurOwn in Progressive Multiple Sclerosis…
finance.yahoo.com - March 30 at 1:36 PM
Brainstorm Cell Therapeutics Inc. [BCLI] moved up 3.06: Why It’s ImportantBrainstorm Cell Therapeutics Inc. [BCLI] moved up 3.06: Why It’s Important
dbtnews.com - March 25 at 11:30 PM
Maxim Group Gives a Buy Rating to Brainstorm Cell Therapeutics (BCLI)Maxim Group Gives a Buy Rating to Brainstorm Cell Therapeutics (BCLI)
smarteranalyst.com - March 25 at 6:30 PM
BrainStorm Announces Positive Data On Cell Therapy NurOwn As Treatment For Progressive MS; Stock UpBrainStorm Announces Positive Data On Cell Therapy NurOwn As Treatment For Progressive MS; Stock Up
nasdaq.com - March 24 at 12:14 PM
Why Is It Moving? Looking Into Why Brainstorm Cells Stock is Trading Higher TodayWhy Is It Moving? Looking Into Why Brainstorm Cell's Stock is Trading Higher Today
msn.com - March 24 at 12:14 PM
BrainStorm Announces Positive Topline Data in Phase 2 Study Evaluating NurOwn® as a Treatment for Progressive MSBrainStorm Announces Positive Topline Data in Phase 2 Study Evaluating NurOwn® as a Treatment for Progressive MS
finance.yahoo.com - March 24 at 7:14 AM
BCLI: Awaiting BrainStorm’s Decision on NurOwn® BLA Filing…BCLI: Awaiting BrainStorm’s Decision on NurOwn® BLA Filing…
finance.yahoo.com - March 4 at 4:49 PM
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Brainstorm Cell Therapeutics Inc. - BCLISHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Brainstorm Cell Therapeutics Inc. - BCLI
prnewswire.com - February 24 at 8:24 PM
BrainStorm to Present at SVB Leerink 10th Global Healthcare ConferenceBrainStorm to Present at SVB Leerink 10th Global Healthcare Conference
finance.yahoo.com - February 23 at 8:19 AM
Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Brainstorm Cell Therapeutics Inc. (BCLI) InvestigationBronstein, Gewirtz & Grossman, LLC Notifies Investors of Brainstorm Cell Therapeutics Inc. (BCLI) Investigation
finance.yahoo.com - February 22 at 7:56 PM
FDA Concludes BrainStorms ALS Cell Therapy Lacks Substantial Data For Submission; Shares DropFDA Concludes BrainStorm's ALS Cell Therapy Lacks Substantial Data For Submission; Shares Drop
finance.yahoo.com - February 22 at 2:55 PM
BrainStorm Announces High-Level FDA Feedback on NurOwn® ALS Clinical Development ProgramBrainStorm Announces High-Level FDA Feedback on NurOwn® ALS Clinical Development Program
finance.yahoo.com - February 22 at 9:54 AM
We Think Brainstorm Cell Therapeutics (NASDAQ:BCLI) Needs To Drive Business Growth CarefullyWe Think Brainstorm Cell Therapeutics (NASDAQ:BCLI) Needs To Drive Business Growth Carefully
finance.yahoo.com - February 6 at 8:45 AM
BCLI: Waiting for Guidance from FDA on Potential Path Forward for NurOwn® in ALS…BCLI: Waiting for Guidance from FDA on Potential Path Forward for NurOwn® in ALS…
finance.yahoo.com - February 5 at 1:03 PM
Why BrainStorm Cell Therapeutics Blasted 27.7% Higher TodayWhy BrainStorm Cell Therapeutics Blasted 27.7% Higher Today
finance.yahoo.com - February 4 at 7:57 PM
DateCompanyBrokerageAction
4/22/2021TRACON PharmaceuticalsBTIG ResearchUpgrade
4/1/2021TRACON PharmaceuticalsJonestradingInitiated Coverage
2/10/2021TRACON PharmaceuticalsMaxim GroupInitiated Coverage
12/4/2020TRACON PharmaceuticalsHC WainwrightBoost Price Target
3/1/2019TRACON PharmaceuticalsNeedham & Company LLCReiterated Rating
5/3/2021Genocea BiosciencesRobert W. BairdReiterated Rating
4/13/2021Genocea BiosciencesSVB LeerinkBoost Price Target
7/8/2019Genocea BiosciencesStifel NicolausInitiated Coverage
11/2/2020Aziyo BiologicsTruistInitiated Coverage
11/2/2020Aziyo BiologicsPiper SandlerInitiated Coverage
11/2/2020Aziyo BiologicsCowenInitiated Coverage
11/2/2020Aziyo BiologicsCantor FitzgeraldInitiated Coverage
1/25/2021Ayala PharmaceuticalsNoble FinancialReiterated Rating
12/7/2020Ayala PharmaceuticalsRoth CapitalInitiated Coverage
8/13/2020Ayala PharmaceuticalsRaymond JamesReiterated Rating
8/13/2020Ayala PharmaceuticalsOppenheimerReiterated Rating
6/2/2020Ayala PharmaceuticalsJefferies Financial GroupInitiated Coverage
6/2/2020Ayala PharmaceuticalsCitigroupInitiated Coverage
12/18/2018Brainstorm Cell TherapeuticsDawson JamesReiterated Rating
(Data available from 5/6/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.